JP2023166387A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023166387A5 JP2023166387A5 JP2023129964A JP2023129964A JP2023166387A5 JP 2023166387 A5 JP2023166387 A5 JP 2023166387A5 JP 2023129964 A JP2023129964 A JP 2023129964A JP 2023129964 A JP2023129964 A JP 2023129964A JP 2023166387 A5 JP2023166387 A5 JP 2023166387A5
- Authority
- JP
- Japan
- Prior art keywords
- synthetic
- sulfated
- alkyl
- group
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001542 oligosaccharide Polymers 0.000 claims 6
- 150000002482 oligosaccharides Chemical class 0.000 claims 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 5
- 239000002628 heparin derivative Substances 0.000 claims 5
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000000600 disaccharide group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 claims 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 2
- 229940097043 glucuronic acid Drugs 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 150000002301 glucosamine derivatives Chemical class 0.000 claims 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (5)
- ６～８の糖単位を含む３－Ｏ－硫酸化オリゴ糖と、
３－ＯＳＴ－３酵素により硫酸化された、少なくとも１つの二糖単位と、
少なくとも１つのＩｄｏＡ２Ｓ－ＧｌｃＮＳ３Ｓ又はＩｄｏＡ２Ｓ－ＧｌｃＮＳ３と
を含み、
以下の群：
［Ｒは、－Ｈ、アルキル、置換アルキル、アリール、及び置換アリールから成る群から選択される。］
からなる群から選択される構造を含む、
合成オリゴ糖。 - 以下の構造：
［Ｒは、－Ｈ、アルキル、置換アルキル、アリール、及び置換アリールから成る群から選択される。］
からなる、請求項１に記載の合成オリゴ糖。 - アルキルが、－ＣＨ３若しくは－ＣＨ２ＣＨ３であるか、又は、ｐ－ニトロフェニル基である、請求項１又は２に記載の合成オリゴ糖。
- 以下の構造：
［Ｒは、－Ｈ、アルキル、置換アルキル、アリール、及び置換アリールから成る群から選択される。］
から選択される合成オリゴ糖を含む、抗凝固剤療法を必要とする患者を治療するための薬学的組成物。 - 硫酸化修飾されたグルコサミン（ＧｌｃＮ）残基に結合したグルクロン酸（ＧｌｃＡ）と、硫酸化修飾されたＧｌｃＮ残基に結合したイズロン酸（ＩｄｏＡ）との２糖単位を含む合成ヘパリンアナログであって、
前記合成ヘパリンアナログが、
６～８の糖単位を含む３－Ｏ－硫酸化オリゴ糖と、
３－ＯＳＴ－３酵素により硫酸化された、少なくとも１つの、糖単位と、
少なくとも１つのＩｄｏＡ２Ｓ－ＧｌｃＮＳ３Ｓ、又は少なくとも１つのＩｄｏＡ２Ｓ－ＧｌｃＮＳ３と
を含み、
ここで、前記合成ヘパリンアナログからは、ＧｌｃＡ－ＧｌｃＮＳ３Ｓ６Ｓ ２糖単位が除外され、
前記合成ヘパリンアナログは、ＧｌｃＮＳ６Ｓ残基を含む少なくとも１つの２糖単位を含む、
合成ヘパリンアナログ。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469643P | 2017-03-10 | 2017-03-10 | |
| US62/469,643 | 2017-03-10 | ||
| PCT/US2018/021986 WO2018165656A1 (en) | 2017-03-10 | 2018-03-12 | Short-acting heparin-based anticoagulant compounds and methods |
| JP2019549419A JP7330893B2 (ja) | 2017-03-10 | 2018-03-12 | 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549419A Division JP7330893B2 (ja) | 2017-03-10 | 2018-03-12 | 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023166387A JP2023166387A (ja) | 2023-11-21 |
| JP2023166387A5 true JP2023166387A5 (ja) | 2024-03-22 |
Family
ID=63449042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549419A Active JP7330893B2 (ja) | 2017-03-10 | 2018-03-12 | 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法 |
| JP2023129964A Pending JP2023166387A (ja) | 2017-03-10 | 2023-08-09 | 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549419A Active JP7330893B2 (ja) | 2017-03-10 | 2018-03-12 | 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11903963B2 (ja) |
| EP (1) | EP3579897A4 (ja) |
| JP (2) | JP7330893B2 (ja) |
| CN (2) | CN110446511B (ja) |
| WO (1) | WO2018165656A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11993627B2 (en) | 2017-07-03 | 2024-05-28 | The University Of North Carolina At Chapel Hill | Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides |
| US11865137B2 (en) | 2017-11-03 | 2024-01-09 | The University Of North Carolina At Chapel Hill | Sulfated oligosaccharides having anti-inflammatory activity |
| CN112437667B (zh) | 2018-06-20 | 2024-05-28 | 北卡罗来纳大学查珀尔希尔分校 | 细胞保护方法和组合物 |
| JP2022523638A (ja) | 2019-01-15 | 2022-04-26 | オプティムヴィア、エルエルシー | 改変型硫酸アリール依存性酵素 |
| EP3997238A1 (en) | 2019-07-09 | 2022-05-18 | Optimvia, LLC | Methods for synthesizing anticoagulant polysaccharides |
| JP2023501568A (ja) * | 2019-11-13 | 2023-01-18 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果 |
| WO2023157899A1 (ja) * | 2022-02-17 | 2023-08-24 | 国立大学法人九州大学 | 組換えヘパリン様物質、及びその製造方法 |
| CN115417937B (zh) * | 2022-08-12 | 2023-06-06 | 山东大学 | 一种含双抗凝血酶结合序列的肝素十二糖及其制备方法与应用 |
| CN116120484A (zh) * | 2022-09-01 | 2023-05-16 | 山东大学 | 一种抗凝血肝素寡糖苯联二聚体及其制备方法与应用 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| IT1232939B (it) | 1987-11-06 | 1992-03-10 | Opocrin Spa | Eparan solfato caratterizzato da elevata attivita' antitrombotica, elevata biodisponibilita', assenza di attivita' anticoagulante; suo processo di estrazione da organi e da tessuti e relative composizioni farmaceutiche |
| US4865870A (en) | 1988-07-07 | 1989-09-12 | Becton, Dickinson And Company | Method for rendering a substrate surface antithrombogenic |
| PT93847A (pt) | 1989-04-24 | 1990-11-20 | Harvard College | Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem |
| US5378829A (en) | 1990-04-23 | 1995-01-03 | Akzo N.V. | Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type |
| AU2561792A (en) | 1991-09-06 | 1993-04-05 | Children's Medical Center Corporation | Cell-type specific heparan sulfate proteoglycans and their uses |
| IT1260137B (it) | 1992-04-17 | 1996-03-28 | Alfa Wassermann Spa | Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato |
| US5527785A (en) | 1993-05-14 | 1996-06-18 | The Regents Of The University Of California | Selectin receptor modulating compositions |
| JP3818676B2 (ja) | 1994-07-22 | 2006-09-06 | 生化学工業株式会社 | ヘパラン硫酸６−ｏ−硫酸基転移酵素 |
| IT1271057B (it) | 1994-11-04 | 1997-05-26 | Inalco Spa | Polisaccaridi aventi un elevato contenuto di acido iduronico |
| JP3672359B2 (ja) | 1995-07-24 | 2005-07-20 | 生化学工業株式会社 | ヘパラン硫酸 ２−ｏ−硫酸基転移酵素 |
| JP3713276B2 (ja) | 1995-09-29 | 2005-11-09 | バイオマリン ファーマシューティカル インコーポレイテッド | 炎症反応の軽減のためのヘパリナーゼの使用 |
| US5935824A (en) | 1996-01-31 | 1999-08-10 | Technologene, Inc. | Protein expression system |
| US6861254B1 (en) | 1997-10-24 | 2005-03-01 | Massachusetts Institute Of Technology | Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor |
| US8088604B2 (en) | 1998-04-02 | 2012-01-03 | The Board Of Regents Of The University Of Oklahoma | Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases |
| US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
| US6255088B1 (en) | 1999-05-11 | 2001-07-03 | The Scripps Research Institute | Enzymatic sulfation of biomolecules |
| US6977248B1 (en) * | 1999-08-25 | 2005-12-20 | Massachusetts Institute Of Technology | Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry |
| US7101859B2 (en) | 2000-01-10 | 2006-09-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
| US7507723B2 (en) | 2000-07-07 | 2009-03-24 | Seikagaku Corporation | Hyaluronic acid oligosaccharide fractions and drugs containing the same |
| US8067196B2 (en) | 2001-03-28 | 2011-11-29 | Massachusetts Institute Of Technology | 6-O sulfated polysaccharides and methods of preparation thereof |
| EP1392843B1 (en) | 2001-05-08 | 2017-12-13 | The Board of Regents of the University of Oklahoma | Heparin/heparosan synthase and methods of making and using same |
| DK1401853T3 (da) | 2001-05-25 | 2010-11-01 | Univ Duke | Modulatorer af farmakologiske midler |
| WO2003018598A2 (en) | 2001-08-30 | 2003-03-06 | University College Dublin | Monosaccharide derivatives |
| AU2003247808A1 (en) * | 2002-07-05 | 2004-01-23 | Anders Malmstrom | Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same |
| GB0216861D0 (en) | 2002-07-19 | 2002-08-28 | Univ Birmingham | Saccharide libraries |
| WO2004017910A2 (en) | 2002-08-23 | 2004-03-04 | Neose Technologies, Inc. | Total synthesis of heparin |
| WO2005014619A2 (en) | 2003-03-28 | 2005-02-17 | Thomas Jefferson University | Heparin-binding peptides and uses thereof |
| US20040259142A1 (en) | 2003-06-04 | 2004-12-23 | Imperial College Innovations Limited | Products and methods |
| EP1529785B1 (en) | 2003-10-24 | 2011-03-16 | 3M Innovative Properties Company | Aqueous dispersions of polytetrafluoroethylene particles |
| US7655445B2 (en) | 2003-11-12 | 2010-02-02 | Massachusetts Institute Of Technology | Methods for synthesis of sulfated saccharides |
| JP2008500372A (ja) | 2004-05-26 | 2008-01-10 | カリフォルニア インスティテュート オブ テクノロジー | ニューロン成長の低分子刺激物質 |
| US20050282775A1 (en) | 2004-06-16 | 2005-12-22 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
| US20060229276A1 (en) | 2004-07-28 | 2006-10-12 | Magnus Hook | Use of glycosoaminoglycans for the prevention and treatment of sepsis |
| WO2006124801A2 (en) | 2005-05-12 | 2006-11-23 | The University Of North Carolina At Chapel Hill | Enzymatic synthesis of sulfated polysaccharides |
| US8129148B2 (en) | 2005-08-24 | 2012-03-06 | Seikagaku Corporation | Process for preparation of chondroitin fraction |
| CA2652205A1 (en) | 2006-05-25 | 2007-12-06 | Mallik Sundaram | Low molecular weight heparin composition and uses thereof |
| WO2009014715A2 (en) * | 2007-07-23 | 2009-01-29 | The University Of North Carolina At Chapel Hill | Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues |
| US9351992B2 (en) | 2007-11-02 | 2016-05-31 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
| US20110009361A1 (en) | 2007-12-21 | 2011-01-13 | Glycan Biosciences Pty Ltd | Design and selection of medicaments that modulate the function and activity of interleukin 13 |
| WO2010056765A2 (en) | 2008-11-14 | 2010-05-20 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
| MX2011008119A (es) | 2009-02-02 | 2011-08-24 | Otsuka Chemical Co Ltd | Derivado de acido hialuronico polisulfatado de bajo peso molecular, y medicamento que contiene el mismo. |
| SG175133A1 (en) | 2009-04-09 | 2011-12-29 | Univ North Carolina | Methods of treating edema related to ischemia-reperfusion |
| US20110054236A1 (en) | 2009-08-25 | 2011-03-03 | The Regents Of The University Of Michigan | Compositions and methods for targeting tumors |
| US20120322760A1 (en) | 2009-09-23 | 2012-12-20 | Momenta Pharmaceuticals, Inc. | Methods of treatment with a low molecular weight heparin composition |
| US9226939B2 (en) | 2010-12-01 | 2016-01-05 | The Australian National University | Histone inhibition |
| ES2910476T3 (es) * | 2010-12-23 | 2022-05-12 | Univ North Carolina Chapel Hill | Síntesis quimioenzimática de heparinas de peso molecular ultra bajo estructuralmente homogéneas |
| WO2012116048A1 (en) | 2011-02-22 | 2012-08-30 | Rensselaer Polytechnic Institute | Single step heparosan n-deacetylation and depolymerization for making bioengineered heparin |
| US8519189B2 (en) | 2011-06-01 | 2013-08-27 | University Of British Columbia | Polymers for reversing heparin-based anticoagulation |
| EP2964255B1 (en) | 2013-03-08 | 2020-11-04 | CSL Behring GmbH | Treatment and prevention of remote ischemia-reperfusion injury |
| EP3011043B1 (en) | 2013-06-17 | 2022-05-11 | The University of North Carolina At Chapel Hill | Reversible heparin molecules |
| US11993627B2 (en) | 2017-07-03 | 2024-05-28 | The University Of North Carolina At Chapel Hill | Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides |
| US11865137B2 (en) | 2017-11-03 | 2024-01-09 | The University Of North Carolina At Chapel Hill | Sulfated oligosaccharides having anti-inflammatory activity |
| CN112437667B (zh) | 2018-06-20 | 2024-05-28 | 北卡罗来纳大学查珀尔希尔分校 | 细胞保护方法和组合物 |
| JP2023501568A (ja) | 2019-11-13 | 2023-01-18 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果 |
| JP2023004753A (ja) | 2021-06-28 | 2023-01-17 | 日本航空電子工業株式会社 | コネクタ |
-
2018
- 2018-03-12 JP JP2019549419A patent/JP7330893B2/ja active Active
- 2018-03-12 WO PCT/US2018/021986 patent/WO2018165656A1/en unknown
- 2018-03-12 CN CN201880020095.XA patent/CN110446511B/zh active Active
- 2018-03-12 CN CN202310342719.2A patent/CN116622006A/zh active Pending
- 2018-03-12 US US16/492,858 patent/US11903963B2/en active Active
- 2018-03-12 EP EP18764628.6A patent/EP3579897A4/en active Pending
-
2023
- 2023-07-17 US US18/222,910 patent/US20240066048A1/en active Pending
- 2023-08-09 JP JP2023129964A patent/JP2023166387A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023166387A5 (ja) | ||
| US5380716A (en) | Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation | |
| JP2016523535A5 (ja) | ||
| JP2020510119A5 (ja) | ||
| Li et al. | Heparosan‐Derived Heparan Sulfate/Heparin‐Like Compounds: One Kind of Potential Therapeutic Agents | |
| JP3345020B2 (ja) | 合成ポリサッカライド、それらの製造法およびそれらを含む医薬組成物 | |
| TW580391B (en) | Sulfated oligosaccharides having anticoagulant/antithrombotic activity | |
| Jin et al. | Preactivation-based, iterative one-pot synthesis of anticoagulant pentasaccharide fondaparinux sodium | |
| JP3594990B2 (ja) | ３−デオキシオリゴ糖、その製造方法およびそれを含有する医薬組成物 | |
| JP2019501263A (ja) | 硫酸化ヘパリン由来オリゴ糖及びその調製法と施用 | |
| JP4695756B2 (ja) | 新規な五糖類、その製造法およびそれを含む医薬組成物 | |
| EP2356128A1 (en) | Oligosaccharide compounds for use in mobilising stem cells | |
| WO2005092348A1 (ja) | ヘパリン様オリゴ糖含有ｈｇｆ産生促進薬剤 | |
| CA2258146C (fr) | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| US20100075922A1 (en) | Heparins including at least one covalent bond with biotin or a biotin derivative, method for preparing same and use thereof | |
| EP0582665A1 (en) | Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation | |
| JP4587148B2 (ja) | 平滑筋細胞増殖促進剤 | |
| JP2005290383A (ja) | ６−ｏ−硫酸化ｎ−アセチルヘパロサン及び造血幹細胞増殖助剤 | |
| Wessel | Heparinoid mimetics | |
| JP5153324B2 (ja) | 硬組織形成促進剤 | |
| US6329351B1 (en) | Semi-synthetic sulphaminoheparosansulphates having high anti-metastatic activity and reduced haemorrhagic risk | |
| US7285536B2 (en) | Anti-cancer therapeutic compounds | |
| RU2176915C2 (ru) | Полусинтетические сульфаминогепаросансульфаты, имеющие высокую антиметастатическую активность и пониженный геморрагический риск | |
| AU706002B2 (en) | New anticoagulants | |
| EP2721044B1 (en) | Synthetic pentasaccharides having short half-life and high activity |